14 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 19052168 | POLYPEPTIDES AND USES THEREOF | FISCHER, JOSEPH | 1658 | Final Rejection | Feb 12, 2025 |
| 18467137 | THERAPEUTIC BINDING MOLECULES | SKOKO III, JOHN JOSEPH | 1643 | Final Rejection | Sep 14, 2023 |
| 18025883 | A Scoring Method for an Anti-B7H4 Antibody-Drug Conjugate Therapy | XIAO, YAN | 1642 | Non-Final OA | Mar 11, 2023 |
| 18169497 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | BUNNER, BRIDGET E | 1647 | Final Rejection | Feb 15, 2023 |
| 17998388 | FORMULATIONS OF ANTI-IL-33 ANTIBODIES | BELYAVSKYI, MICHAIL A | 1644 | Final Rejection | Nov 10, 2022 |
| 17962610 | PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES | ELENISTE, PIERRE PAUL | 1622 | Final Rejection | Oct 10, 2022 |
| 17906123 | THERAPEUTIC METHODS FOR THE TREATMENT OF SUBJECTS WITH RISK ALELLES IN IL33 | KAPUSHOC, STEPHEN THOMAS | 1683 | Non-Final OA | Sep 12, 2022 |
| 17819185 | COMBINATION THERAPY | VAN DRUFF, SYDNEY | 1643 | Final Rejection | Aug 11, 2022 |
| 17759388 | ANTI-avB8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE | HADDAD, MAHER M | 1641 | Non-Final OA | Jul 25, 2022 |
| 17755605 | METHODS OF USING IL-33 ANTAGONISTS | MERTZ, PREMA MARIA | 1674 | Final Rejection | May 03, 2022 |
| 17755604 | ANTI IL-33 THERAPEUTIC AGENT FOR TREATING RENAL DISORDERS | BERHANE, SELAM | 1675 | Final Rejection | May 03, 2022 |
| 17617875 | COMBINATION THERAPY COMPRISING AN ANTI-CD19 ANTIBODY DRUG CONJUGATE AND A PI3K INHIBITOR OR A SECONDARY AGENT | PETERS, ALEC JON | 1641 | Final Rejection | Dec 09, 2021 |
| 17599374 | COMPOUNDS AND CONJUGATES THEREOF | GAUGER, PAUL RANDALL | 1629 | Final Rejection | Sep 28, 2021 |
| 17271108 | COMBINATION THERAPY | CANELLA, KAREN A | 1643 | Final Rejection | Feb 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial